Table of Contents
View abstract. Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol repressive impact on marble-burying behavior: involvement of CB1 receptors. Behav Pharmacol 2010; 21( 4 ):353 -8. View abstract. Chesney E, Oliver D, Green A, et al. Adverse impacts of cannabidiol: a methodical review and meta-analysis of randomized medical trials. Neuropsychopharmacology. 2020. View abstract.
The Impacts of Cannabidiol Oil on Noninvasive Procedures of Muscle Damage in Men. Med Sci Sports Exerc. 2021. View abstract. Cole TB, Saitz R. Cannabis and Impaired Driving. JAMA. 2020; 324( 21 ):2163 -2164. View abstract. Consroe P, Sandyk R, Snider SR. Open label examination of cannabidiol in dystonic movement conditions. Int J Neurosci 1986; 30( 4 ):277 -82.
Consroe P, Wolkin A. Cannabidiol-antiepilpetic drug contrasts and interactions in experimentally caused seizures in rats. J Pharmacol Exp Ther 1977; 201( 1 ):26 -32. View abstract. Consroe PF, Wokin AL. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977; 29( 8 ):500 -1. View abstract. Cortopassi J. Warfarin dosage modification required after cannabidiol initiation and titration.
2020; 77( 22 ):1846 -1851. View abstract. Couch DG, Prepare H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. Palmitoylethanolamide and Cannabidiol Avoid Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019; 25( 6 ):1006 -1018. View abstract. Covington TR, et al. Handbook of Nonprescription Drugs. 11th ed.
Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic impacts of cannabidiol (CBD) in generalized social stress and anxiety disorder: an initial report. J Psychopharmacol 2011; 25( 1 ):121 -30. View abstract. Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Patients with Moderate to Moderate Symptoms (Prospect Research Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
View abstract. Crippa JAS, Zuardi AW, Guimares FS, et al. Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Employees Handling COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Requirement Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Amongst Frontline Health Care Workers Throughout the COVID-19 Pandemic: A Randomized Medical Trial.
2021 Aug 2; 4( 8 ): e2120603. View abstract. Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the result of various meal compositions, whole milk, and alcohol on cannabidiol direct exposure and security in healthy subjects. Epilepsia. 2020; 61( 2 ):267 -277. View abstract. Cryan JF, Markou A, Lucki I.
Trends Pharmacol Sci 2002; 23( 5 ):238 -45. View abstract. Czgny Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Representative 2021; 11( 1 ):8951. View abstract. Dalton WS, Martz R, Lemberger L, et al. Influence of cannabidiol on delta-9-tetrahydrocannabinol impacts. Clin Pharmacol Ther 1976; 19( 3 ):300 -9. View abstract. Darweesh RS, Khamis TN, El-Elimat T.
Naunyn Schmiedebergs Arch Pharmacol. 2020. View abstract. Davis BH, Beasley TM, Amaral M, et al. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clin Pharmacol Ther 2021; 110( 5 ):1368 -1380. View abstract. de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Condition. Mov Disord.
View abstract. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Effectiveness and unfavorable occasion profile of cannabidiol and medicinal marijuana for treatment-resistant epilepsy: Systematic evaluation and meta-analysis. Epilepsy Behav. 2020; 102:106635. View abstract. de Faria SM, de Morais Fabrcio D, Tumas V, et al.
J Psychopharmacol. 2020 Jan 7:269881119895536. View abstract. De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLo, S One 2011; 6( 12 ): e28159. View abstract. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and possible therapeutic function in epilepsy and other neuropsychiatric conditions.
View abstract. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Medication. 2017 May 25; 376( 21 ):2011 -2020. View abstract. Devinsky O, Kraft K, Rusch L, Fein M, Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Stage 1 Clinical Research Study.
View abstract. Devinsky O, Marsh E, Friedman D, et la. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar; 15( 3 ):270 -8. View abstract. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17; 378( 20 ):1888 -1897.
Devinsky O, Verducci C, Thiele EA, et al. Open-label usage of highly cleansed CBD (Epidiolex) in patients with CDKL5 shortage condition and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018 Sep; 86:131 -137. Epub 2018 Jul 11. View abstract. Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Positioning in Arrange V of Specific FDA-Approved Drugs Consisting Of Cannabidiol; Corresponding Modification to Allow Requirements.
Fed Regist. 2018 Sep 28; 83( 189 ):48950 -3. View abstract. Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol Raises Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. Pediatr Neurol. 2020; 105:59 -61. View abstract. El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like impact of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Available at: https://www.
Table of Contents
Latest Posts
Using Cbd (Cannabidiol) For Parkinson's Disease Symptoms now available in New Zealand
My Experience Using Cbd Oil For Parkinson's Symptoms in Portland
Best Cbd Oil For Parkinson's Disease - 2022 Guide - American ... now available in United States - limited period only
All Categories
Navigation
Latest Posts
Using Cbd (Cannabidiol) For Parkinson's Disease Symptoms now available in New Zealand
My Experience Using Cbd Oil For Parkinson's Symptoms in Portland
Best Cbd Oil For Parkinson's Disease - 2022 Guide - American ... now available in United States - limited period only